PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
FromBio narrowed its operating loss sharply in the second quarter of 2026, but shrinking shareholders' equity and short-term liquidity pressure keep balance-sheet stability as the central watch point.
Second-quarter 2026 revenue was KRW 14.66 billion with an operating loss of KRW 0.55 billion, a sharp narrowing from the prior quarter's KRW 3.28 billion operating loss.
Full-year 2025 revenue rose year over year to KRW 72.16 billion, but the company posted an operating loss of KRW 18.6 billion and a net loss of KRW 23.2 billion, marking a fourth consecutive annual loss.
Following a trading halt tied to a 5-for-1 par-value consolidation (July 14 to August 10, 2026), shares hit the daily upper limit on the first day trading resumed.
The company is broadening beyond its Boswellia- and mastic gum-based individually approved health-supplement ingredients into cosmetics, probiotics, and a hair-loss cell therapy pipeline.
As of end-March, current assets of KRW 14.3 billion versus current liabilities of KRW 35.7 billion point to short-term liquidity pressure.
FromBio, established in 2006, is a health-supplement company that owns its full value chain from ingredient discovery to production and distribution.
Its core products are a joint-and-cartilage health line based on Boswellia extract and a stomach-health line based on mastic gum, both of which hold individually approved functional-ingredient status from Korea's Ministry of Food and Drug Safety and have long accounted for a large share of revenue.
The company recently launched a new probiotics product, Family365 Biome, expanding into the probiotics category. Its cosmetics subsidiary, FromBio Cosmetic, produces mastic-based cosmetics and is shifting from an online-centric model toward expanded offline distribution.
Beyond supplements, FromBio is developing a hair-loss cell therapy using differentiated adipose-derived stem cells (dADSCs), a new business aimed at transforming the company from a supplement maker into a cell-therapy developer.
That pipeline has completed general toxicity testing and is now undergoing remaining non-clinical evaluations including biodistribution and tumorigenicity studies, with a target of filing an Investigational New Drug (IND) application with Korean regulators in 2027.
The core of its ingredient competitiveness lies in exclusive rights to individually approved ingredients, and FromBio has held such exclusivity over Boswellia extract, mastic gum, African mango extract, and krill oil.
On the competitive front, a growing number of later entrants launching similar functional products has intensified competition in the supplement market, which is cited as one factor behind the slowdown in performance.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩15.9B | -₩3.9B | −24.3% |
| 2025Q3 | ₩18.3B | -₩4.4B | −24.3% |
| 2025Q4 | ₩19.5B | -₩8B | −41.0% |
| 2026Q1 | ₩19.2B | -₩3.3B | −17.1% |
| 2026Q2 | ₩14.7B | -₩600M | −3.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩99.3B | ₩900M | ₩3.2B | 0.9% | 3.7% | 7.8% |
| 2023 | ₩66.7B | -₩15.4B | -₩11.1B | −23.1% | −14.5% | 29.5% |
| 2024 | ₩67.2B | -₩24.3B | -₩25.3B | −36.1% | −50.3% | 65.3% |
| 2025 | ₩72.2B | -₩18.6B | -₩22.5B | −25.8% | −80.1% | 149.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
Consolidated revenue in 2025 rose to KRW 72.16 billion from KRW 67.18 billion a year earlier, yet the company posted an operating loss of KRW 18.6 billion and a net loss of KRW 23.2 billion (owners' net loss of KRW 22.46 billion), marking a fourth straight annual loss.
The operating margin was -25.8%, an improvement from -36.1% in 2024 but still deeply negative.
On a quarterly basis, revenue rose from KRW 15.86 billion with an operating loss of KRW 3.85 billion in the second quarter of 2025 to KRW 18.30 billion with an operating loss of KRW 4.44 billion in the third quarter, and in the fourth quarter revenue reached KRW 19.51 billion while the operating loss widened to KRW 8.00 billion, producing the quarter's largest owners' net loss of KRW 10.62 billion.
In the first quarter of 2026, revenue was KRW 19.17 billion with an operating loss of KRW 3.28 billion and an owners' net loss of KRW 3.62 billion, while in the second quarter revenue declined to KRW 14.66 billion yet the operating loss narrowed markedly to KRW 0.55 billion and the owners' net loss to KRW 1.17 billion.
Revenue trends and profitability did not always move in the same direction, with advertising and sales-commission expenses acting as a key swing factor in results. Indeed, in the first quarter of 2026 combined advertising and sales-commission expenses reached roughly 59% of revenue.
Full-year operating cash flow in 2025 was negative KRW 10.07 billion, an improvement from negative KRW 14.70 billion in 2024, but internal cash generation remains absent.
Total equity has steadily declined from KRW 87.01 billion in 2022 to KRW 26.14 billion in 2025, making the erosion of capital a central variable for financial stability.
Korea's health-supplement market was worth roughly KRW 6.4 trillion in 2025, up 5.2% year over year, with household penetration reaching 82.6%. Growth of 4.8% to 6.2% annually is projected for 2026 through 2028, suggesting the market will maintain moderate but steady expansion.
Within the market, individually approved ingredients targeting specific functions grew 12.5% and were cited as a key driver, a trend that aligns with FromBio's business model.
Globally, however, the United States and China hold the top two market shares, meaning Korean companies' overseas expansion remains at a relatively early stage.
On the competitive front, a wave of new entrants launching similar functional products has intensified price and marketing competition, which has weighed on the profitability of incumbents including FromBio.
Individually approved ingredients retain exclusivity for a considerable period after registration, but the constant possibility of new competitors entering with similar functional claims makes the durability of this barrier a point to watch.
In the biotech segment, cell-therapy development in Korea remains at an early stage of the broader regenerative medicine industry, an area requiring a long time horizon before commercialization.
The company launched a new probiotics product, Family365 Biome, entering the probiotics category and diversifying its portfolio beyond the existing joint- and stomach-health focus.
In its biotech segment, it completed a 12-month long-term stability test on the cell bank built under a contract manufacturing agreement with Matica Biolabs, strengthening its chemistry, manufacturing, and controls (CMC) foundation.
Its dADSCs hair-loss cell therapy has completed repeated-dose toxicity testing and is undergoing remaining non-clinical evaluations including biodistribution and tumorigenicity studies, with an IND filing to Korean regulators targeted for 2027.
Patent registration for the blood-brain-barrier permeation technology platform of PepsGen, a biotech venture in which FromBio holds roughly a 10% stake, was also reported to be imminent.
On ingredient diversification, the company is pursuing a two-track strategy for its mastic gum-based composite ingredient (FHH-MG), seeking both a domestic individually approved ingredient status and a U.S. FDA New Dietary Ingredient (NDI) certification in parallel.
Financially, the company completed a 5-for-1 par-value consolidation that reduced outstanding shares from 28.31 million to 5.662 million, stating this would serve as an opportunity to restructure its finances and strengthen profitability-focused management.
The CEO purchased 280,000 treasury shares on the open market after the first-quarter loss widened, signaling an effort to stabilize the stock.
The share price trades at a discount relative to net asset value, remaining below book value per share.
However, because the company has posted net losses for several consecutive years, a conventional price-to-earnings framework is difficult to apply, and market valuation may be more sensitive to the pace of future profit improvement and balance-sheet stabilization.
No dividends have been paid in recent years, so the central variable for investment judgment is less about dividend appeal and more about the pace of business-model transition and earnings recovery.
With the 5-for-1 consolidation having reduced the number of shares outstanding, future trading patterns and supply-demand dynamics also warrant continued observation.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
The second-quarter 2026 operating loss narrowed sharply to KRW 0.55 billion from KRW 3.28 billion in the prior quarter. That the loss shrank even as revenue declined suggests some degree of cost control or selling-expense efficiency took hold.
Whether this trend continues into subsequent quarters will be a key gauge of the durability of any earnings improvement.
The company's business axis is expanding beyond core supplements into cosmetics, a new probiotics product, and hair-loss cell therapy development. Progress in CMC foundation-building, including completed cell-bank stability testing with Matica Biolabs, has been made, alongside a concrete 2027 IND filing target. Multiple new business lines progressing in parallel could reduce dependence on any single segment.
FromBio holds exclusive rights to multiple individually approved ingredients including Boswellia extract and mastic gum. The individually approved ingredient category has shown relatively high growth within Korea's supplement market, aligning the business model with broader market trends. Preparations for overseas expansion, including a pursuit of U.S. FDA NDI certification, are also underway.
Total equity declined steadily from KRW 87.01 billion in 2022 to KRW 26.14 billion in 2025. The company posted an operating loss of KRW 18.6 billion and a net loss of KRW 23.2 billion in 2025 alone, extending the loss streak. Continued equity erosion could add further pressure to financial-health indicators.
Advertising and sales-commission expenses have made up a disproportionately high share of revenue. In the first quarter of 2026, the combined total reached roughly 59% of revenue. Marketing spend aimed at driving sales growth risks repeatedly offsetting profitability gains.
As of end-March, current assets stood at KRW 14.3 billion against current liabilities of KRW 35.7 billion. Short-term borrowings totaled KRW 32.55 billion while cash and cash equivalents amounted to only KRW 1.49 billion. Near-term repayment pressure and the potential need for additional financing remain financial risks.
With current liabilities substantially exceeding current assets and sizable short-term borrowings, cash and cash equivalents remain relatively thin. Operating cash flow has stayed negative for several consecutive years, raising the likelihood of continued reliance on external financing.
If the trend of declining total equity persists, managing financial soundness will become increasingly important.
Competition in the supplement market is intensifying as more later entrants enter the field. Individually approved ingredients can eventually be reclassified as generally notified ingredients after a certain period, meaning exclusivity is not permanent, which is worth noting. Changes in government approval and functional-claim review standards could also affect the business.
The dADSCs hair-loss cell therapy remains at the non-clinical stage, and the path to an IND filing, clinical entry, and eventual commercialization could take a long time. Development timelines could be delayed or altered depending on non-clinical trial outcomes. Given the nature of drug development, additional R&D funding needs may arise.
The third-quarter 2026 quarterly report should show whether the loss-narrowing trend continues and whether the advertising and sales-commission expense ratio improves.
Progress on U.S. FDA NDI certification for the mastic-gum composite ingredient (FHH-MG) and the outcome of the domestic individually approved ingredient application for hair health should become clearer.
Progress on financial-structure stabilization—short-term debt repayment, current-ratio improvement, and any need for additional financing—warrants monitoring.
Completion of remaining non-clinical studies for the dADSCs hair-loss cell therapy and whether an IND application is filed with Korean regulators will be the key event.
This is the point to check how much revenue from new categories, such as the Family365 Biome product, is being reflected in overall results.
FromBio showed early signs of earnings improvement by sharply narrowing its operating loss in the second quarter of 2026, but four consecutive annual losses through 2025 and steadily shrinking total equity remain unresolved challenges.
The structurally high ratio of selling expenses to revenue is a key variable for the durability of any profit improvement, and current liabilities substantially exceeding current assets as of end-March point to short-term financial risk.
On the other hand, the entry barrier provided by individually approved ingredients, diversification into cosmetics and probiotics, and non-clinical progress in the hair-loss cell therapy pipeline are cited as medium- to long-term growth drivers.
The 5-for-1 par-value consolidation and the CEO's treasury-share purchases can be read as signals of intent to stabilize supply-demand conditions and management.
Going forward, whether the loss-narrowing trend continues in coming quarters, the pace of balance-sheet improvement, and progress on the biotech pipeline's non-clinical studies and IND filing are the key variables to confirm together. This report is for informational purposes only and does not include a buy or sell recommendation.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.